title: When patients on target-specific oral anticoagulants need surgery.
abstract: The target-specific oral anticoagulants (TSOACs), eg, dabigatran, rivaroxaban, and apixaban, are changing the way we manage thromboembolic disease. At the same time, many clinicians wonder how best to manage TSOAC therapy when patients need surgery. An in-depth understanding of these drugs is essential to minimize the risk of bleeding and thrombosis perioperatively.
authors.affiliation: Assistant Professor, Hospital Medicine Section, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora Mary.Anderson@ucdenver.edu.
authors.forename: Mary
authors.initials: M
authors.lastname: Anderson
authors.affiliation: Professor of Medicine, Division of Hematology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora.
authors.forename: Kathryn L
authors.initials: KL
authors.lastname: Hassell
authors.affiliation: Associate Professor, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences; Pharmacy Clinical Specialist, Cardiology/Anticoagulation, University of Colorado Hospital, Aurora.
authors.forename: Toby C
authors.initials: TC
authors.lastname: Trujillo
authors.affiliation: Assistant Professor, Hospital Medicine Section, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora doi:10.3949/ccjm.81a.13168.
authors.forename: Brian
authors.initials: B
authors.lastname: Wolfe
mesh_terms: D000925:Anticoagulants / Q000145:classification / Q000494:pharmacology; D016063:Blood Loss, Surgical / Q000517:prevention & control*; D002985:Clinical Protocols; D006801:Humans; D019990:Perioperative Care / Q000379:methods; D019106:Postoperative Hemorrhage / Q000517:prevention & control*; D013514:Surgical Procedures, Operative / Q000009:adverse effects / Q000379:methods; D013923:Thromboembolism / Q000517:prevention & control*
chemical_list: D000925:Anticoagulants